文献速递前列腺癌

基于无创诊断策略免前列腺活检的根治性前列腺切除术:一项前瞻性单中心研究

Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-12-18

这项前瞻性单中心研究纳入57例高度疑似前列腺癌患者,采用由诊断预测模型(含PI-RADS评分与PSAD)和18F-PSMA-1007 PET/CT组成的无创诊断策略,免活检直接行根治性前列腺切除术。主要终点临床显著前列腺癌的阳性预测值为98.2%(56/57,95%CI:90.6-100%),作者认为免活检根治性前列腺切除术具有初步可行性。

要点

  • 57例患者基于无创诊断策略免活检直接行根治性前列腺切除术。
  • 临床显著前列腺癌阳性预测值为98.2%(56/57,95%CI:90.6-100%)。
  • 任何级别前列腺癌阳性预测值100%,高级别前列腺癌阳性预测值73.7%(42/57,95%CI:60.3-84.5%)。

核心结论

  • 作者提出序贯采用诊断预测模型和18F-PSMA-1007 PET/CT检查的无创诊断策略来诊断前列腺癌。
  • 尽管存在一些局限性,作者的初步发现提示免前列腺活检直接行根治性前列腺切除术具有潜在可行性。

研究设计与样本

  • 前瞻性单中心研究,于2022年11月10日至2023年12月1日期间纳入57例患者。
  • 所有57例患者均未先行前列腺活检,而是基于由诊断预测模型(包含PI-RADS评分和PSAD)与18F-PSMA-1007 PET/CT检查组成的无创诊断策略直接行根治性前列腺切除术。
  • 共筛查371例临床疑似前列腺癌患者,其中57例符合标准并同意参与研究。

主要发现

  • 中位PSAD为0.56(0.42-0.82)ng/mL²;13例(22.8%)患者PI-RADS评分为4,44例(77.2%)患者PI-RADS评分为5。
  • 18F-PSMA-1007 PET/CT的中位SUVmax为21.6(15.8-33.0)。
  • 57例直接接受根治性前列腺切除术的患者中,临床显著前列腺癌的阳性预测值为98.2%(56/57,95%CI:90.6-100%)。
  • 仅1.8%(1/57,95%CI:0.0-9.4%)的患者被诊断为临床不显著前列腺癌(ISUP分级=1,Gleason评分=3+3)。
  • 任何级别前列腺癌和高级别前列腺癌的阳性预测值分别为100%和73.7%(42/57,95%CI:60.3-84.5%),无人出现假阳性结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论中提及「Despite some limitations」,但未具体列出局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate biopsy is the most common approach for diagnosing prostate cancer (PCa); however, it has inherent limitations, such as the invasive procedure, postoperative complications, and false negative results. We aimed to provide a noninvasive diagnostic strategy for patients with highly suspected PCa and to evaluate the feasibility of performing biopsy-spared radical prostatectomy. METHODS: This prospective study included a total of 57 patients between November 10, 2022, and December 1, 2023. All 57 patients underwent radical prostatectomy without prior prostate biopsy based on a noninvasive diagnostic strategy consisting of a diagnostic prediction model [comprised of the prostate imaging-reporting and data system (PI-RADS) score and prostate-specific antigen density (PSAD)] and the 18F-prostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/computed tomography (CT) examination. The primary endpoint was the positive predictive value (PPV) of clinically significant PCa [the International Society of Urological Pathology (ISUP) grade ≥2, Gleason score ≥3 + 4]. The secondary endpoints were a PPV of any-grade PCa (ISUP grade ≥ 1, Gleason score ≥3 + 3) and high-grade PCa (ISUP grade ≥3, Gleason score ≥4 + 3), and the false positive rate of the diagnostic strategy. RESULTS: Of the 371 screened patients with clinically suspected PCa, 57 patients fulfilled the criteria and consented to participate in this study. The median PSAD level was 0.56 (0.42-0.82) ng/mL2; 13 (22.8%) patients were identified as having a PI-RADS score of 4, and 44 (77.2%) patients with a PI-RADS score of 5. The median SUVmax of 18F-PSMA-1007 PET/CT was 21.6 (15.8-33.0). For the 57 enrolled patients who received radical prostatectomy directly, the PPV of clinically significant PCa was 98.2% [56/57, 95% confidence interval (CI): 90.6-100%]. Only 1.8% (1/57, 95% CI: 0.0-9.4%) of patients were diagnosed with clinically insignificant PCa (ISUP grade = 1, Gleason score = 3 + 3). The PPV of any-grade PCa and high-grade PCa were 100% and 73.7% (42/57, 95% CI: 60.3-84.5%), respectively. No one had a false positive result. CONCLUSIONS: We proposed a noninvasive diagnostic strategy consisting sequentially of a diagnostic prediction model and the 18F-PSMA-1007 PET/CT examination for diagnosing PCa. Despite some limitations, our initial findings suggest the potential feasibility of radical prostatectomy without prior prostate biopsy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Wang C, Xie Q, Yuan L, et al. Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study. Prostate Cancer Prostatic Dis. 2024. PMID: 39695194. doi:10.1038/s41391-024-00931-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。